We are pleased to announce that Gael Touya, has been appointed President and Chief Executive Officer of Aptar effective September 1, 2026. He succeeds Stephan B. Tanda, who will retire after nearly a decade as President and CEO.
Learn more: https://t.co/SZm193yZJm
We're pleased to announce the integration of Aptar #DigitalHealth's Migraine Buddy®, migraine tracking app, with ŌURA Ring. This collab aims to deliver deeper, more personalized insights into migraine patterns & potential triggers. Learn more https://t.co/G0Uf2b2zwf
Deeply honored to receive the endorsement of the legendary @dionnewarwick! Her friendship has been a true blessing over the years. Grateful for the bond formed through former Lt. Gov Sheila Oliver & our shared commitment to initiatives like Nurture NJ, improving maternal health in our state.
Aptar Digital Health announces it has acquired Healint, which will broaden its portfolio in neurology and strengthen its global footprint for digital health deployment. Read full Press Release. https://t.co/oQUiys3R0S
#AptarPharma#AptarDigitalHealth#Neurology#Migraine
Proud to announce a historic investment in our efforts to combat the opioid crisis in NJ – increasing funding for harm reduction initiatives, addiction treatment access, recovery programs, supportive housing, & more – fully funded by settlement payments from the opioid industry.
The #NJEastAsiaMission has shown that @NJIT has a global reach. Three outstanding @NJITAlumni are also part of the mission: Adam Shain, VP of Aptar; Chao Yan, Founder & CEO of NuEnergy; and Tiffany Bohlin, president & CEO of Muller Bohlin Associates.
@AdamMShain
Studies show that patients who must self-administer medication receive an average of 17 minutes of training from their HCP. With no formal training process in place, it often varies widely across specialties and highlights a need for better patient onboarding.
#NobleSpeaksPatient
An article from Dr. Stuart Madden, Chief Scientific Officer at Neurelis in Drug, Delivery, & Development discusses the benefits and challenges related to the nasal drug delivery route vs other delivery methods. #neurelis#drugdelivery&development
https://t.co/G6nYbzihwg
Dyslexia holds back too many of our children in school but most importantly in life.
We are going to have the largest, most comprehensive approach to supporting students with dyslexia in the country. I'm proud of this moment. https://t.co/9B1XUz0cR5
#AptarPharma partners with @Stallergenes_Greer to develop a novel #digitalhealth ecosystem for Allergen Immunotherapy Treatment - a #connecteddevice & mobile app to help improve dose compliance & adherence, thus optimizing patient treatment outcomes. https://t.co/7LlH8HXr0M
“The partnership with REBO allows us to advance our market knowledge for emerging trends and leverage our manufacturing, regulatory, and innovation expertise.” - Jerome Magniet, Aptar President of Global Market Development
Learn more via @PackagingEurope: https://t.co/0q4VAjoEH6
ALIGN, Aptar’s employee resource group for Women, is in the process of onboarding ambassadors to start activities on promoting equality of opportunity and inclusion in all regions. https://t.co/Uhk30xXXuQ #WeAreAptar#EmployeeResourceGroup#Diversity#AptarALIGN
India has 32% of the global burden of #respiratory diseases. Conducive healthcare ecosystem & Govt. interventions will surely help tackle the burden but the onus is also at an individual level. Together, let's fight this threat and help India breathe free. https://t.co/w0TzgbVWOa